

Randomised Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3.

No registrations found.

Ethical review	Positive opinion
Status	Recruitment stopped
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON25773

Source

Nationaal Trial Register

Brief title

PORTEC-3

Health condition

Endometrial carcinoma

Sponsors and support

Primary sponsor: Leiden University Medical Center (LUMC), Department of Clinical Oncology

Source(s) of monetary or material Support: Dutch Cancer Society (KWF Kankerbestrijding, CKTO 2006-04)

Intervention

Outcome measures

Primary outcome

5-year actuarial overall survival

5-year actuarial failure-free survival (with failure defined as relapse or death due to endometrial carcinoma or to treatment complications).

Secondary outcome

1. quality of life;
2. severe treatment related morbidity;
3. 5-year rates of vaginal, pelvic and distant relapse;

Study description

Background summary

Background:

The PORTEC-1 trial (1990-1997) has demonstrated that postoperative external beam radiation therapy (EBRT) for stage 1 endometrial cancer significantly increases 5-year local control (96% versus 85%), but without a difference in survival. The currently ongoing PORTEC-2 trial for intermediate-risk endometrial carcinoma patients investigates whether vaginal brachytherapy, compared to EBRT, provides equally high rates of vaginal control and survival, with less toxicity and better quality of life.

Patients with stage IC (deep myometrial invasion) grade 3 tumors have a higher risk of recurrence and endometrial carcinoma related death. These patients were registered during the PORTEC-1 accrual period and received EBRT. Compared to the PORTEC-1 patients who were randomized to EBRT, stage IC grade 3 cases had an inferior prognosis, with 58% 5-year survival versus 83-86% for grade 1-2 and 74% for IB grade 3, mainly due to a higher risk of distant metastases. In multivariate analyses grade 3 was the most important adverse prognostic factor with hazard ratios for relapse and for endometrial carcinoma related death of 5.4 ($p=0.0001$) and 5.5 ($p=0.0004$). These findings are confirmed by literature data. Stage I and II grade 3 tumors, unfavorable histologic types (serous and clear cell cancers) and stage III tumors are at increased risk of relapse and death (50% 5-year survival).

First results of trials using adjuvant chemotherapy for advanced stage endometrial carcinoma show reduction of recurrence rates and increased survival rates. Omitting pelvic radiation would increase the risk of pelvic relapse. The concurrent use of chemotherapy and radiotherapy has become standard for many tumor sites, as both local control and survival rates are improved. However, this has not yet been investigated for endometrial carcinoma. A RTOG phase II trial of concurrent chemotherapy and radiation therapy followed by adjuvant chemotherapy for high-risk and advanced stage endometrial carcinoma used 2 cycles of cisplatin during radiotherapy, followed by 4 adjuvant cycles of cisplatin and paclitaxel at 4-week intervals. This phase II trial, showing combination therapy to be feasible and having

promising outcome data, was the basis for the PORTEC-3 study. However, in PORTEC-3 the cisplatin has in the adjuvant phase been replaced by carboplatin to reduce toxicity.

Objectives:

Establish whether treatment with concurrent radiotherapy and chemotherapy, followed by adjuvant chemotherapy, improves overall survival and failure-free survival of patients with high-risk and advanced stage endometrial carcinoma, in comparison with pelvic radiation therapy alone. Secondary objectives are to establish and compare the rates of severe (grades 3 and 4) treatment-related toxicity, pelvic and distant recurrence, and compare quality of life.

Study design, population, intervention:

In this multicenter trial 500 patients with stage I or II endometrial adenocarcinoma with high-risk features or stage IIIA or IIIC endometrial carcinoma who meet the inclusion criteria will be randomly allocated to external beam pelvic radiotherapy (control arm; 48.6 Gy in 1.8 Gy fractions), or pelvic radiotherapy with concurrent chemotherapy (2 cycles of cisplatin 50 mg/m² in week 1 and 4), followed by adjuvant chemotherapy (4 cycles of carboplatin AUC 5 and paclitaxel 175 mg/m² at 3-week intervals; experimental arm).

Patients will be stratified for participating group (Dutch CGOG vs. UK NCRI); mode of surgery; stage (IB vs. IC vs. II vs. III); and histological type (endometrioid carcinoma vs. serous and clear cell carcinoma). The accrual period will be 5 years.

Endpoints and statistics:

Primary study endpoints will be 5-year actuarial overall survival, and 5-year actuarial failure-free survival (FFS). Failure is defined as relapse, or death due to endometrial carcinoma or due to treatment complications. Secondary endpoints will be quality of life, severe treatment related morbidity, and rates of vaginal, pelvic and distant relapse.

The principal aim is to detect with sufficient power (80%) a difference in the 5-year overall survival rate of 12.5% (based on an expected 5-year OS in the RT arm of 50%; hazard ratio for combined modality treatment (CMT) 0.68) with a two-sided test at significance level $\alpha=0.05$. This requires 215 events to be observed, and a target number of 500 patients for this trial.

Collaboration in the Intergroup setting with the NCRI will ensure sufficient and timely patient inclusion in this trial. In case of rapid inclusion (150 patients per year) the target number will be increased to 800 patients within the 5-year accrual period to detect a 10% difference in 5-year OS with a power of 80%.

Side studies:

Tumour samples will be collected and saved in a dedicated tissue bank for immunohistochemical studies and tissue micro-array analysis. Aims are to identify new prognostic and predictive markers, compare these to traditional factors, and develop targets for molecular therapy.

Study objective

The addition of concurrent and adjuvant chemotherapy to postoperative radiation therapy will increase 5-year overall survival and failure-free survival of patients with high-risk and advanced stage endometrial carcinoma.

Study design

Primary outcomes are 5-year OS and FFS
Long-term results at 7 and 10 years will be evaluated

Intervention

Patients are randomised (1:1) to receive external beam pelvic radiotherapy (a standard arm; 48.6 Gy in 1.8 Gy fractions), or pelvic radiotherapy with concurrent chemotherapy (2 cycles of cisplatin) followed by adjuvant chemotherapy (4 cycles of carboplatin and paclitaxel; experimental arm).

Contacts

Public

Leiden University Medical Center (LUMC)
Carien L. Creutzberg
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5263027

Scientific

Leiden University Medical Center (LUMC)
Carien L. Creutzberg
Albinusdreef 2
Leiden 2300 RC
The Netherlands
+31 (0)71 5263027

Eligibility criteria

Inclusion criteria

1. Histologically confirmed endometrial carcinoma, with one of the following postoperative FIGO 2009 stages and grade:
 - A. Stage IA with myometrial invasion, grade 3 with documented LVSI;
 - B. Stage IB grade 3;
 - C. Stage II;
 - D. Stage IIIA or IIIC; or IIIB if parametrial invasion only;

E. Stage IA (with myometrial invasion), IB, II, or III with serous or clear cell histology.

2. WHO-performance status 0-2;

3. WBC $\geq 3.0 \times 10^9/L$;

4. Platelets $\geq 100 \times 10^9/L$;

5. Bilirubin $\leq 1.5 \times UNL$;

6. ASAT/ALAT $\leq 2.5 \times UNL$;

7. Written informed consent.

Exclusion criteria

1. Previous malignancy, except for basal cell carcinoma of the skin, < 10 yrs;

2. Previous pelvic radiotherapy;

3. Hormonal therapy or chemotherapy for this tumor;

4. Macroscopic stage IIB for which Wertheim type hysterectomy;

5. Prior diagnosis of Crohn's disease or ulcerative colitis;

6. Residual macroscopic tumor after surgery;

7. Creatinine clearance ≤ 60 ml/min (calculated according to Cockcroft) or ≤ 50 ml/min (EDTA clearance, or measured creatinine clearance);

8. Impaired cardiac function, prohibiting the infusion of large amounts of fluid during cisplatin therapy;

9. Peripheral Neuropathy \geq grade 2.

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Masking:	Open (masking not used)
Control:	Active

Recruitment

NL	
Recruitment status:	Recruitment stopped

Start date (anticipated):	01-10-2006
Enrollment:	500
Type:	Actual

IPD sharing statement

Plan to share IPD: Undecided

Plan description

After publication of long-term results, IPD will be shared after a scientific proposal has been evaluated and approved by the trial group (e.g., for meta analysis)

Ethics review

Positive opinion	
Date:	10-07-2006
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL719
NTR-old	NTR729
Other	METC Leiden-Den Haag-Delft : METC LUMC P06.031
ISRCTN	ISRCTN14387080

Study results

Summary results

Wortman BG, Post CCB, Powell ME, et al.

Radiotherapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of Three-Dimensional Conformal Radiotherapy versus Intensity-Modulated Radiotherapy.

Int J Radiat Oncol Biol Phys. 2021, in press.

Post CCB, de Boer SM, Powell ME, et al.

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial.

Int J Radiat Oncol Biol Phys. 2021 Mar 15;109(4):975-986. doi: 10.1016/j.ijrobp.2020.10.030. Epub 2020 Oct 28.

De Boer SM, Powell ME, Mileskin L, et al.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.

Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. PMID: 31345626

De Boer SM, Powell ME, Mileskin L, et al.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.

Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12

De Boer SM, Wortman BG, Bosse T, et al.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer.

Ann Oncol. 2018 Feb 1;29(2):424-430

De Boer SM, Powell ME, Mileskin L, et al.

Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.

Lancet Oncol. 2016 Aug;17(8):1114-26. doi: 10.1016/S1470-2045(16)30120-6.

Blinman P, Mileskin L, Khaw P, et al.

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial. ANZGOG and PORTEC Group.

Br J Cancer. 2016 Nov 8;115(10):1179-1185. doi: 10.1038/bjc.2016.323

Jameson MG, McNamara J, Bailey M, et al.

Results of the Australasian (Trans-Tasman Oncology Group) radiotherapy benchmarking exercise in preparation for participation in the PORTEC-3 trial.

J Med Imaging Radiat Oncol. 2016 Aug;60(4):554-9. doi: 10.1111/1754-9485.12447.